Company Overview
Molbio Diagnostics Limited, a point-of-care diagnostics company, provides healthcare technologies to diagnose infectious and non-communicable diseases. It manufactures and sells chip based diagnostic devices, chips and reagents, X-ray equipment's, and single/dual detectors. It also offers disposable POCT devices, which includes dengue, malaria, and COVID-19 tests; Tabletop analysers, a portable machine that are used to perform molecular or immunodiagnostic tests to detect infectious diseases, such as tuberculosis, human papillomavrus, STIs, and GI disorders. In addition, the company offers Truenat, a multi-disease real-time polymerase chain reaction platform that enables treatment decisions for various infectious and non-communicable diseases, such as tuberculosis, human immunodeficiency virus, malaria, viral hepatitis, COVID-19, dengue, chikungunya, influenza, H1N1, HPV/cervical cancer, cholera, leprosy, etc.; and Truenat assays. The company was incorporated in 2000 and is based in Verna, India.
Why Investors Should Care
Return on capital employed stands at 16.5%.
Net profit has compounded at 7682.3% per year over the last five years.
Revenue has grown at a 63.7% CAGR over the past five years.
Operating margin of 20.4% supports profitability.
Carries low leverage with a debt-to-equity ratio of 0.34.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Mar 2026 Revenue of ₹1,414.96 Cr (+41.9% YoY); net profit ₹166.59 Cr.
- Trailing 12 Months Year-on-year growth — revenue +309.6%, earnings +14.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 63.7%, profit CAGR 7682.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 63.72% |
| 1 Year: | 309.60% |
Compounded Profit Growth
| 5 Years: | 7,682.28% |
| 1 Year: | 14.81% |
Stock Price Performance
| 1 Year: | +20.93% |
| 6 Months: | - |
| 3 Months: | - |
| 1 Month: | +3.36% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- RSI (14)45.49 · Neutral
P/E of 85.69 is above the sector median of 35.90 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 63.7% over 5 years.
- Profit CAGR of 7682.3% over 5 years.
- Generates positive free cash flow.
CONS
- Trading at a high P/E of 85.7.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MOLBIO Molbio Diagnostics Limited NSEPHARMA | 1,259.70 | 85.69 | ₹14,279.39 Cr | 0.00% | 16.50% | 14.25% | 63.72% | 7,682.28% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,758.00 | 34.88 | ₹4.22 L Cr | 0.91% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 9,162.00 | 83.32 | ₹2.43 L Cr | 0.32% | 18.96% | 15.32% | 10.98% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,615.30 | 73.73 | ₹1.76 L Cr | 0.81% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,135.00 | 25.30 | ₹1.13 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 6 | LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA | 634.25 | 165.17 | ₹1.10 L Cr | 0.00% | 7.21% | 5.65% | 35.38% | 66.99% |
| 7 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 7,604.50 | 52.35 | ₹1.09 L Cr | 0.25% | 19.20% | 20.48% | 14.85% | 33.34% |
| 8 | LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA | 2,002.50 | 98.99 | ₹1.08 L Cr | 0.12% | 19.53% | 16.77% | 3.77% | 4.00% |
| 9 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,330.90 | 31.92 | ₹1.08 L Cr | 0.99% | 14.86% | 11.27% | 7.23% | 11.45% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Jun 2025 | Jun 2026 |
|---|---|---|
| Revenue | 99.71 Cr | 408.38 Cr |
| Cost of Revenue | 35.17 Cr | 149.68 Cr |
| Gross Profit | 64.53 Cr | 258.69 Cr |
| Operating Expenses | 92.11 Cr | 175.18 Cr |
| Operating Income | -27.58 Cr | 83.51 Cr |
| EBITDA | -15.35 Cr | 103.68 Cr |
| Interest Expense | 3.61 Cr | 10.70 Cr |
| Pretax Income | -31.28 Cr | 75.91 Cr |
| Tax Provision | -7.33 Cr | 23.16 Cr |
| Net Income | -23.71 Cr | 58.75 Cr |
| Diluted EPS | -2.06 | 5.10 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue | 322.43 Cr | 819.73 Cr | 997.48 Cr | 1,414.96 Cr |
| Cost of Revenue | 145.58 Cr | 343.67 Cr | 417.29 Cr | 581.62 Cr |
| Gross Profit | 176.84 Cr | 476.06 Cr | 580.19 Cr | 833.34 Cr |
| Operating Expenses | 163.27 Cr | 261.71 Cr | 351.25 Cr | 553.95 Cr |
| Operating Income | 13.58 Cr | 214.35 Cr | 228.94 Cr | 279.39 Cr |
| EBITDA | 47.91 Cr | 184.34 Cr | 254.99 Cr | 326.17 Cr |
| Interest Expense | 6.65 Cr | 13.69 Cr | 16.01 Cr | 31.39 Cr |
| Pretax Income | 9.54 Cr | 129.64 Cr | 194.43 Cr | 231.14 Cr |
| Tax Provision | 12.98 Cr | 46.10 Cr | 55.85 Cr | 67.00 Cr |
| Net Income | -72.60 L | 101.95 Cr | 145.10 Cr | 166.59 Cr |
| Diluted EPS | -0.06 | 8.85 | 12.59 | 14.46 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Total Assets | 1,034.21 Cr | 1,221.06 Cr | 1,461.56 Cr | 2,148.42 Cr |
| Current Assets | 616.74 Cr | 823.16 Cr | 929.83 Cr | 1,384.84 Cr |
| Cash & Equivalents | 6.97 Cr | 12.68 Cr | 114.75 Cr | 355.53 Cr |
| Inventory | 347.02 Cr | 315.14 Cr | 435.91 Cr | 449.26 Cr |
| Receivables | 188.75 Cr | 425.45 Cr | 271.66 Cr | 408.74 Cr |
| Total Liabilities | 296.87 Cr | 392.22 Cr | 494.27 Cr | 839.65 Cr |
| Current Liabilities | 257.55 Cr | 342.76 Cr | 441.67 Cr | 557.36 Cr |
| Long Term Debt | 98.50 L | 15.12 Cr | 6.14 Cr | 212.41 Cr |
| Total Debt | 118.53 Cr | 183.62 Cr | 146.93 Cr | 450.08 Cr |
| Total Equity | 721.48 Cr | 823.38 Cr | 968.39 Cr | 1,169.34 Cr |
| Shares Outstanding | 11.52 Cr | 11.52 Cr | 11.52 Cr | 11.52 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Operating Cash Flow | 64.13 Cr | 9.57 Cr | 287.10 Cr | 50.38 Cr |
| Investing Cash Flow | -39.73 Cr | -45.01 Cr | -122.65 Cr | -93.22 Cr |
| Financing Cash Flow | 18.24 Cr | -31.55 Cr | -26.15 Cr | 276.07 Cr |
| Capital Expenditure | -14.50 Cr | -16.11 Cr | -54.66 Cr | -50.02 Cr |
| Free Cash Flow | 49.63 Cr | -6.54 Cr | 232.44 Cr | 36.30 L |
| Net Change in Cash | 42.64 Cr | -66.99 Cr | 138.30 Cr | 233.23 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Gross Margin % | 54.8% | 58.1% | 58.2% | 58.9% |
| Operating Margin % | 4.2% | 26.1% | 23.0% | 19.7% |
| Net Margin % | -0.2% | 12.4% | 14.5% | 11.8% |
| ROE % | -0.1% | 12.4% | 15.0% | 14.2% |
| ROCE % | 1.7% | 24.4% | 22.4% | 17.6% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MOLBIO
Molbio Diagnostics Ltd. Share Price Today - Molbio Diagnostics Ltd. Stock Price Live NSE/BSE - CNBC TV18
<a href="https://news.google.com/rss/articles/CBMiiAFBVV95cUxOaG1OdGR1MHZ5QXFxQTlFbTlEdkZ6Z182QU54QjVDSzRCTHJKTVdUb2lBdFVYVWwxOENxaWFaSnJFNUZuU1dPWWFnZFUtbW5WX1pjWVliU1d4MzFkSF9aejh6a3J4aW5IaXlyYlBmOG1sVHgxRG5OV3BwTFhlQm9RUVNTUkZzSWky?oc=5"…
Molbio Diagnostics Limited (MOLBIO.NS) stock price, news, quote and history - Yahoo Finance Australia
<a href="https://news.google.com/rss/articles/CBMiZ0FVX3lxTE1vY0FnMTY1OXQ3d0JZQnJjSXVhb2l1WnRYQ3BkYXZGQWQwVUowSHBwTVN1dmdqQkN1Z1dscGFSZWNjMUpzRVV5WC1zWlBfVWtkbjBTd0FSZ1lOdThwcXd4Ml9FUTdScDQ?oc=5" target="_blank">Molbio Diagnostics Limited (…
Molbio Diagnostics shares jump 5% as HDFC MF buys 1.99% stake via bulk deal | Newly listed stock up 71% from IPO price - TradingView
<a href="https://news.google.com/rss/articles/CBMi_wFBVV95cUxNeFpLWENYYU5qdkFQOWlUUUNJZFFQZVBMcWtwZHFEcGxQY1g3emVDc2hSTGowdzI2M3dxNG5GWlJyWWdQdlJURGJ4NUpYc2lZMnZIX0YtOVVlRXJnUnAxTHdPMWlsZXRLSVdTc1lWUlZIZTR1Z1pfUWRwY0t3MGVfa0hMbVJIdzNNaXZRNG…
Molbio Diagnostics Stock Soars 9% As It Becomes Jefferies Top Med Tech Pick At Initiation - NDTV Profit
<a href="https://news.google.com/rss/articles/CBMi7gFBVV95cUxNQlJMS2RfZE54cnhNUTBWZS1PeGg2LVRxZ0tWcW9LLWhYUUZ3ajRwdjlDUzFuOThYakR5cFByLXVFMi1JSUxMWV9tejd2ZDliUkZ6aHNhVjR2TmxkVV9fTGlXNktIbmNlUkhlWGc1WTZjRUtMZGxiSFlNZ09ncmV1cUFKaTB3V2UtNDhyWW…
Tech picks: Indian Hotels among 5 stocks to buy for healthy returns in short term - The Economic Times
<a href="https://news.google.com/rss/articles/CBMixwJBVV95cUxQMnFhaHRiYnNkZkhhM21KYVRrOVNLNTJFRk5nLWdqTVpBRmJkMV9jcGVialN0T2pWb3hwVC04Z1NjdF9EVDBLcE44aDY0c1pibFdfS1R5NnB0cV9Hemg5WkhfeHRWWGZBRHdKYUtaQmZnUTdhOE83dUR5YTdFbmNmQlBvY2ZOamVaLXVlZE…
Molbio Diagnostics Limited (MOLBIO.NS) stock historical prices and data - Yahoo Finance Singapore
<a href="https://news.google.com/rss/articles/CBMiY0FVX3lxTE1oZ1ZNalVkeGxOTzNaZXBqNC1DSG5rRXp3bWRvWWdhd0FlbzRpeFlvaDU5OXdCbF9GYTRtbGlwOF9XeHZmREIwSERwZjVOc2x4Wi11RjJxd2VNRFd2bjd4TXo5OA?oc=5" target="_blank">Molbio Diagnostics Limited (MOLBI…
MOLBIO — Frequently Asked Questions
What is the current share price of Molbio Diagnostics Limited (MOLBIO)?
As of 2026-10-24 04:55 IST, Molbio Diagnostics Limited (MOLBIO) trades at ₹1,259.70 on NSE. Its 52-week range is ₹1,036.65 to ₹1,574.40.
What is the market capitalisation of MOLBIO?
Molbio Diagnostics Limited (MOLBIO) has a market capitalisation of ₹14,279.39 Cr on NSE.
What is the P/E ratio of MOLBIO?
MOLBIO trades at a trailing price-to-earnings (P/E) ratio of 85.69. The industry average P/E is 35.90. Its price-to-book (P/B) ratio is 11.95.
What is the return on equity (ROE) of MOLBIO?
MOLBIO has a return on equity (ROE) of 14.25%. Its return on capital employed (ROCE) is 16.50%.
Is MOLBIO a good stock to buy?
This page provides a data-driven analysis of Molbio Diagnostics Limited (MOLBIO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.